Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia

• Main Authors: Yang, Haiyan, Chennamaneni, Lohitha Rao, Ho, Melvyn Wai Tuck, Ang, Shi Hua, Tan, Eldwin Sum Wai, Jeyaraj, Duraiswamy Athisayamani, Yeap, Yoon Sheng, Liu, Boping, Ong, Esther H. Q., Joy, Joma Kanikadu, Wee, John Liang Kuan, Kwek, Perlyn, Retna, Priya, Dinie, Nurul, Nguyen, Thuy Thi Hanh, Tai, Shi Jing, Manoharan, Vithya, Pendharkar, Vishal, Low, Choon Bing, Chew, Yun Shan, Vuddagiri, Susmitha, Sangthongpitag, Kanda, Choong, Meng Ling, Lee, May Ann, Kannan, Srinivasaraghavan, Verma, Chandra Shekhar, Poulsen, Anders, Lim, Sharon, Chuah, Charles Thuan Heng, Ong, Tiong Sin, Hill, Jeffrey, Matter, Alex, Nacro, Kassoum
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2020
• Subjects: Science::Medicine; Rodent Models; Inhibitors
• Online Access: https://hdl.handle.net/10356/139169
• Institution: Nanyang Technological University

Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by bcr-abl1, a constitutively active tyrosine kinase fusion gene responsible for an abnormal proliferation of leukemic stem cells (LSCs). Inhibition of BCR-ABL1 kinase activity offers long-term relief to CML patients. However, for...